Provided by Tiger Fintech (Singapore) Pte. Ltd.

SILO PHARMA INC.

0.5598
-0.0423-7.03%
Post-market: 0.5407-0.0191-3.41%19:45 EDT
Volume:2.43M
Turnover:1.21M
Market Cap:7.46M
PE:-0.56
High:0.5978
Open:0.5805
Low:0.3960
Close:0.6021
52wk High:3.37
52wk Low:0.3960
Shares:13.32M
Float Shares:13.12M
Volume Ratio:2.10
T/O Rate:18.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0002
EPS(LYR):-1.1936
ROE:-90.03%
ROA:-43.96%
PB:1.52
PE(LYR):-0.47

Loading ...

Company Profile

Company Name:
SILO PHARMA INC.
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
3
Office Location:
677 North Washington Boulevard,Sarasota,Florida,United States
Zip Code:
34236
Fax:
- -
Introduction:
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Directors

Name
Position
Eric Weisblum
Chairman, Chief Executive Officer and President
Jeff Pavell
Director
Kevin Muñoz
Director
Wayne D. Linsley
Director

Shareholders

Name
Position
Eric Weisblum
Chairman, Chief Executive Officer and President
Daniel Ryweck
Chief Financial Officer